DLA Piper advised Quipt Home Medical in $42.5 million public offering and private placement
On April 25, 2023, Quipt Home Medical Corp. (“Quipt”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, closed a $42.5 million bought deal public offering of common shares.
The public offering was conducted through a syndicate of underwriters led by Beacon Securities Limited and Canaccord Genuity Corp. on behalf of a syndicate of underwriters including Echelon Wealth Partners Inc., Raymond James Ltd., Stifel GMP, Eight Capital, Leede Jones Gable Inc. and M Partners Inc. Concurrent with the closing of the public offering, the underwriters also completed a brokered private placement. Read more about this transaction here.
DLA Piper Canada and DLA Piper US acted for Quipt with a team in Canada that included Robbie Grossman, Sydney A. Kert, Kevin Fritz, Alexandre Lamoureux and Sophie Gadbois, and a team in the US that included Larry Nishnick and Kathryn Fortin.
Quipt CFO, Hardik Mehta, said, “DLA Piper’s cross border team provided us great practical advise, understands our business and we are thrilled to have them by our side.”
Quipt provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions.
